Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The study design is a non-randomized, open label, single center Phase II trial. Eligible
patients are women who have a confirmed diagnosis of ovary, fallopian tube cancer or primary
peritoneal serous papillary carcinoma who have relapsed or are refractory to therapy after
primary treatment of their disease.
Patients will be treated with bendamustine Hydrochloride 90 mg/m2 intravenously on days 1(± 1
day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose
will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
20 patients will be enrolled in the study.
OBJECTIVES Hypothesis/Rationale: To determine the efficacy and safety of bendamustine
hydrochloride, in women with platinum and taxane refractory ovarian cancer.